ResearcherGuizhou UniversityActive in the last 2 years

Tingting Feng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0004-5118-7626; OpenAlex author ID A5062039965. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2023: 1 paper · 2024: 1 paper

Papers 2

Gemcitabine Inhibits the Progression of Pancreatic Cancer by Restraining the WTAP/MYC Chain in an m6A-Dependent Manner. Last author DOI 10.4143/crt.2022.1600 ↗
Preparation and Characterization of PLGA-based Magnetic Polymer Nanoparticles for Targeting Pancreatic Adenocarcinoma. Co-author DOI 10.2174/1381612829666230324091555 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xiaofeng Xue · 1 shared paper, 2024 · strength 0.26
- Paper Gemcitabine Inhibits the Progression of Pancreatic Cancer by Restraining the WTAP/MYC Chain in an m6A-Dependent Manner. DOI 10.4143/crt.2022.1600 ↗
Pei Cao · 1 shared paper, 2024 · strength 0.26
- Paper Gemcitabine Inhibits the Progression of Pancreatic Cancer by Restraining the WTAP/MYC Chain in an m6A-Dependent Manner. DOI 10.4143/crt.2022.1600 ↗
Xiuliang Zhu · 1 shared paper, 2023 · strength 0.18
- Paper Preparation and Characterization of PLGA-based Magnetic Polymer Nanoparticles for Targeting Pancreatic Adenocarcinoma. DOI 10.2174/1381612829666230324091555 ↗
Liangji Lu · 1 shared paper, 2023 · strength 0.18
- Paper Preparation and Characterization of PLGA-based Magnetic Polymer Nanoparticles for Targeting Pancreatic Adenocarcinoma. DOI 10.2174/1381612829666230324091555 ↗
Zuhua Wang · 1 shared paper, 2023 · strength 0.18
- Paper Preparation and Characterization of PLGA-based Magnetic Polymer Nanoparticles for Targeting Pancreatic Adenocarcinoma. DOI 10.2174/1381612829666230324091555 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.